Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics is supported by a compelling combination of accelerating commercial traction and expanding regulatory reach, with MYQORZO now approved in Canada, the U.S., China, the European Union, and the UK, reinforcing a broader global launch path. The company’s 2Q26 results strengthen the thesis further, as product sales of about $25MM, U.S. net sales of $23.0MM, over 2,500 REMS-certified HCPs, and more than 700 prescribing HCPs suggest meaningful early adoption and market expansion. Fundamentally, the pipeline adds upside through aficamten’s strong clinical data in oHCM and nHCM, including statistically significant improvements in exercise performance, symptoms, and biomarkers, while multiple upcoming regulatory milestones could extend the label and deepen the long-term growth profile.

Cytokinetics is fundamentally pressured by its lack of commercial-stage revenue, since it remains in clinical development with its most advanced candidate only in Phase 3 and no profitable products in the market. Even though ACACIA met both dual primary endpoints at week 36 and showed statistically significant gains in KCCQ-CSS and maximal exercise performance, the benefit faded after a four-week washout period, underscoring dependence on continued dosing and raising durability concerns. Its valuation is highly concentrated in aficamten at 76%, while execution, regulatory rejection, competitive displacement, and the need for external funding leave the business exposed to meaningful downside if development or commercialization falters.